MREONasdaqPharmaceutical PreparationsFiscal year ends December 31
Mereo BioPharma Group plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$0.30−0.00 (-0.30%)
Close on Oct 19, 2026
- Market cap
- $242.76M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.7479 (−85.26%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Mereo BioPharma Group plc reported revenue of $500.00K for fiscal 2025. Free cash flow was -$25.35M.
Revenue
$500.00K
FY2025
Operating income
-$34.20M
TTM Q2 2026
Free cash flow
-$25.35M
TTM Q2 2026
EPS, diluted
-$0.04
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $242.76M
- P/E ratio
- –
- Price to sales
- 485.51
- Price to book
- 8.47
- Dividend yield
- –
- Free cash flow yield
- -10.44%
Fundamentals
- Revenue
- $500.00K
- Net income
- -$28.10M
- EPS, diluted
- -$0.04
- Free cash flow
- -$25.35M
- Book value per share
- $0.04
- Diluted shares
- 804M
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$34.20M
Net income
-$28.10M
EPS, diluted
-$0.04
Free cash flow
-$25.35M
Reported periodTrailing twelve months